Abbott Laboratories ABT
Abbott Laboratories is a diversified healthcare company that develops and sells medical devices, diagnostics, nutrition products, and established generic pharmaceuticals worldwide. Abbott shows solid financial health (ND/EBITDA 2.32) and a high gross margin (56.85%), but earnings growth has collapsed by -47.5% and the valuation (P/E 32.78) is not cheap. The potential catalyst is the approval of the Grail test, which could re-accelerate growth.
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
Abbott Laboratories is a diversified healthcare company that develops and sells medical devices, diagnostics, nutrition products, and established generic pharmaceuticals worldwide. Abbott shows solid financial health (ND/EBITDA 2.32) and a high gross margin (56.85%), but earnings growth has collapsed by -47.5% and the valuation (P/E 32.78) is not cheap. The potential catalyst is the approval of the Grail test, which could re-accelerate growth.
Score by category
| Category | Score |
|---|---|
| Financial health | 6.1 |
| Quality / Moat | 5.8 |
| Valuation | 4.7 |
| Growth | 3.6 |
| Dividend | 5.8 |
| Momentum | 3.0 |
| Risk & Context | 7.8 |
OVERALL SCORE: 5.4/10
Context and risks
Moderate regulatory risk in the US and exposure to FDA approvals, such as the Grail test, which are a key factor for future growth. Pricing pressure in the healthcare sector is a structural risk.
News considered in the analysis
- FDA Advisors Said It Should Approve the Grail Multicancer Blood Test. The Stock Rises Sharply. — La aprobación del test de detección múltiple de cáncer Grail por parte de la FDA es un hito regulatorio material que abre un mercado significativo y valida una inversión clave, aunque la aprobación final aún no está asegurada.
- Abbott Laboratories (ABT) is Facing Segment Competition and Sluggish Nutrition Recovery — La presión competitiva en segmentos clave y la lenta recuperación de la nutrición son vientos en contra conocidos que ya pesan en el crecimiento y el margen, pero no son información nueva.
- Gilead vs. Abbott: Which Dividend Healthcare Stock Offers the Better Risk-Reward? — Artículo comparativo sin información nueva sobre Abbott.
- NVST vs. ABT: Which Stock Is the Better Value Option? — Comparativa de valor sin información nueva.
- Abbott (ABT) Registers a Bigger Fall Than the Market: Important Facts to Note — Comentario sobre la evolución del precio sin información fundamental nueva.
Verdict: Hold. Wait for the Grail test approval to materialize and for an improvement in the earnings trend before increasing the position.
Main risk: The slow recovery of the nutrition division and increased competition in medical devices could prolong weak earnings growth, weighing on the valuation.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →